Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Zynga (ZNGA) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Brian Nowak saying the company's in-game innovation, starting with Poker, is resulting in higher engagement and monetization. 2. Citi (C) upgraded to Neutral from Sell at UBS with analyst Saul Martinez saying he sees an improved risk/reward at current share levels. Global growth "looks resilient," protectionist policies have not emerged, and the path forward for structural reforms in the U.S. "is not as clear." 3. Comerica (CMA) upgraded to Outperform from Market Perform at FBR Capital. 4. Camping World (CWH) upgraded to Buy from Neutral at Goldman Sachs with analyst David Tamberrino saying he expects growth to continue despite late-cycle concerns. 5. Humana (HUM) upgraded to Buy from Hold at Argus with analyst David Toung saying he is upbeat about its growth outlook following the termination of its merger deal with Aetna (AET). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Piper Sandler analyst R. Scott Siefers raised the firm's price target on Comerica to $56 from $54 and keeps a Neutral rating on the shares. The Q1 results from the Midwest banks contained no major surprises, and they are "hopefully nearing a positive" net interest income inflection, the analyst tells investors in a research note. Despite the fluid rate environment, managements broadly reiterated NII guides, says Piper.

RBC Capital lowered the firm's price target on Humana to $353 from $415 but keeps an Outperform rating on the shares after its Q1 results and updated outlook. While the management is taking 2025 adjusted EPS growth targets off the table for now, the company also stressed its continued commitment to margin improvement next year, indicating that pulling guidance does not signal that 2025 is a no-growth year, the analyst tells investors in a research note. RBC adds however that it is still cutting its FY25 EPS outlook for Humana to $20.28 from $23.87.

Oppenheimer analyst Michael Wiederhorn lowered the firm's price target on Humana to $370 from $415 and keeps an Outperform rating on the shares. The firm says Humana handily topped Q1 2024 expectations and maintained FY2024 guidance, highlighted by improving IP trends in March, leading to an in-line MLR without any contribution from favorable Q4 PPRD that seems likely. Looking forward, management pulled its 2025 growth guidance of $6-$10 EPS due to the rate pressures and TBC limitations, and also extended its return to 3% margins beyond 2026, says Oppenheimer. Overall, Humana continues to face the magnified impact from MA due to its significant exposure, but also boasts a portfolio with significant long-term margin upside, the firm adds.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here

Affirms FY 2024 Insurance segment benefit ratio of approximately 90%. Raises 2024 individual Medicare Advantage annual membership growth by 50,000 to now anticipate annual growth of approximately 150,000, or 2.8%.

Reports Q1 revenue $29.61B, consensus $28.47B.